
Jackie Mulryne, partner at Morgan Lewis
5 January 2026FeaturesEuropeJackie Mulryne
Key EU and UK regulatory changes to watch for in 2026
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Europe
13 April 2026 New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.
Europe
13 April 2026 Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Europe
9 April 2026 In light of Emotional Perception AI, the UKIPO has rewritten the rules for “mixed inventions". Matt Jefferies and Eric McNeil of Marks & Clerk explore what this pivot means for applicants protecting their AI technology.
